Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's main market is Finland, where it is the clear market leader. Orion’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets. In other markets Orion’s products are sold by several collaboration partners. All of Orion's manufacturing plants and most of its R&D operations are in Finland. Orion’s headquarters are in Espoo. In the year 2018 Orion employed around 3200 people, net sales were 977.5 million € and R&D expenses 104.0 million €

Orion R&D

Orion's pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation. There are around 500 professionals working in R&D. Orion has offices in Espoo, Turku and Kuopio in Finland, and in Nottingham in England and Mumbai in India. In its own R&D, Orion focuses on early-phase drug development. Orion has launched several proprietary products onto the market in various therapy areas. In the initial and final stages of research projects Orion works together with skilled partners, such as universities and other pharmaceutical companies. The partnerships allow Orion to work on a large number of research projects simultaneously while focusing on its own core competence. Successful research also benefits our partners.